CN102573821A - 保持体重的戒烟法及营养补充剂 - Google Patents

保持体重的戒烟法及营养补充剂 Download PDF

Info

Publication number
CN102573821A
CN102573821A CN201080043603XA CN201080043603A CN102573821A CN 102573821 A CN102573821 A CN 102573821A CN 201080043603X A CN201080043603X A CN 201080043603XA CN 201080043603 A CN201080043603 A CN 201080043603A CN 102573821 A CN102573821 A CN 102573821A
Authority
CN
China
Prior art keywords
component
vitamin
group
individuality
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080043603XA
Other languages
English (en)
Chinese (zh)
Inventor
哈兰·克莱顿·比利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/571,391 external-priority patent/US20100021570A1/en
Application filed by Individual filed Critical Individual
Publication of CN102573821A publication Critical patent/CN102573821A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080043603XA 2009-09-30 2010-09-29 保持体重的戒烟法及营养补充剂 Pending CN102573821A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/571,391 2009-09-30
US12/571,391 US20100021570A1 (en) 2006-06-21 2009-09-30 Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US12/893,910 2010-09-29
PCT/US2010/050774 WO2011041451A2 (en) 2009-09-30 2010-09-29 Smoking cessation with body weight maintenance and nutritional supplement
US12/893,910 US8889194B2 (en) 2006-06-21 2010-09-29 Smoking cessation with body weight maintenance and nutritional supplement

Publications (1)

Publication Number Publication Date
CN102573821A true CN102573821A (zh) 2012-07-11

Family

ID=43826869

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080043603XA Pending CN102573821A (zh) 2009-09-30 2010-09-29 保持体重的戒烟法及营养补充剂

Country Status (5)

Country Link
US (1) US8889194B2 (https=)
JP (1) JP2013506678A (https=)
CN (1) CN102573821A (https=)
CA (1) CA2776160A1 (https=)
WO (1) WO2011041451A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105011374A (zh) * 2015-06-05 2015-11-04 深圳市施美乐科技股份有限公司 复合功能型无烟香烟
CN107666836A (zh) * 2015-06-12 2018-02-06 菲利普莫里斯生产公司 电子吸烟制品中的生物学控制
CN110475561A (zh) * 2017-03-23 2019-11-19 美纳里尼制药工业联合股份有限公司 具有抗氧化活性的保健性、饮食性和营养性组合物
CN111315373A (zh) * 2017-10-13 2020-06-19 瑟纳法姆工业合成有限公司 用于预防和/或治疗以神经元可塑性下降为特征、特别是突触可塑性下降为特征的中枢神经系统疾病的化合物和组合物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281186A1 (en) * 2008-04-21 2009-11-12 Melissa Lee Composition and Method for Reducing Stress
CA2738357C (en) * 2011-04-07 2019-08-06 Premium Vitamins And Supplements, L.L.C. D/B/A Nugevity Methods and compositions to promote ocular health
CN102860581B (zh) * 2012-09-07 2014-07-30 苏州昆蓝生物科技有限公司 纳米材料结合生物酶技术对烟梗的处理方法
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
WO2015073444A1 (en) * 2013-11-12 2015-05-21 Children's Hospital & Research Center At Oakland Methods and compositions for modulating serotonin levels
TW201618787A (zh) * 2014-10-30 2016-06-01 艾尼納製藥公司 組合物及方法
US10894024B2 (en) * 2014-12-08 2021-01-19 Synaptamine, Inc. Anti-RDS compounds and method of manufacture and administration thereof to induce dopamine homeostatis
CN104872814A (zh) * 2015-05-05 2015-09-02 昌宁德康生物科技有限公司 一种提取烟叶净油的生产方法
CA3208241A1 (en) 2015-08-31 2017-03-09 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
US10183031B2 (en) * 2016-02-22 2019-01-22 Matthew Scott Tucker Compositions containing vitamin D and magnesium
WO2017145056A1 (en) * 2016-02-23 2017-08-31 SINGH, Gurseet Nicotine free herbal composition for smoking de-addiction and treatment of side-effects and/or ailments from smoking
EP3720295A4 (en) * 2017-12-08 2021-09-08 Chromocell Corporation Tryptophan derivatives as sweeteners
US11229667B2 (en) * 2018-02-19 2022-01-25 Fp Nutraceuticals, Llc Magnesium/lithium preparations for neuroprotection and neurotrophic benefits
US20210085596A1 (en) * 2018-02-19 2021-03-25 Food Technology and Design, LLC, DBA FoodPharma Compositions for oral mucoadhesive dosage forms
IT201800004108A1 (it) * 2018-03-29 2019-09-29 Nathura S P A Composizione a base naturale per l’uso nel trattamento dello stress cronico caratterizzato da disturbi dell’umore e/o ansia
WO2019216871A1 (en) * 2018-05-07 2019-11-14 Plant Sensory Systems, Llc Combinations of organic compounds to increase crop production
US10849948B2 (en) 2019-04-16 2020-12-01 The Procter & Gamble Company Supplement for menopause
AU2022245394A1 (en) * 2021-03-26 2023-10-12 Px Ing, Llc The use of paraxanthine to reduce exercise-induced mental fatigue
CN112822323A (zh) * 2021-04-19 2021-05-18 航天神舟智慧系统技术有限公司 二手手机管控认证方法、系统、电子设备及存储介质

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1304048A1 (en) * 2001-10-22 2003-04-23 Ivo Pera Composition to reduce or quit smoking addiction
US20030176358A1 (en) * 1997-03-30 2003-09-18 Mariko Egawa Method of treating environmental stress
CN1462188A (zh) * 2000-07-21 2003-12-17 太阳化学株式会社 抑制吸烟欲的组合物
CN1665511A (zh) * 2002-07-01 2005-09-07 法玛西雅厄普约翰有限责任公司 促使吸烟者戒烟的方法
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596706A (en) 1985-04-12 1986-06-24 Elena Avram Method for eliminating or reducing the desire for smoking
US5596007A (en) 1992-05-18 1997-01-21 Pharmaco Behavioral Associates, Inc. Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine
US5643928A (en) 1992-10-21 1997-07-01 Pharmaco Behavioral Associates, Inc. Human body weight management
US5869505A (en) 1993-02-02 1999-02-09 Keenan; Robert M. Nicotine metabolites and nicotine dependence
US5573774A (en) 1993-02-02 1996-11-12 Keenan; Robert M. Nicotine metabolites, nicotine dependence and human body weight
WO1996000072A1 (en) 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1997018781A1 (en) 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
US6166032A (en) 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5760049A (en) 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5922346A (en) 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6057368A (en) 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
WO2001026642A2 (en) 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
US6431874B1 (en) 1999-10-27 2002-08-13 Goen Corporation Stop smoking method and composition
US6409991B1 (en) 1999-12-15 2002-06-25 Mark Reynolds Treatment and system for nicotine withdrawal
AT411730B (de) * 2002-05-17 2004-05-25 Groke Karl Dr Mittel zur raucher-entwöhnung oder zur alkohol-entwöhnung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176358A1 (en) * 1997-03-30 2003-09-18 Mariko Egawa Method of treating environmental stress
CN1462188A (zh) * 2000-07-21 2003-12-17 太阳化学株式会社 抑制吸烟欲的组合物
EP1304048A1 (en) * 2001-10-22 2003-04-23 Ivo Pera Composition to reduce or quit smoking addiction
CN1665511A (zh) * 2002-07-01 2005-09-07 法玛西雅厄普约翰有限责任公司 促使吸烟者戒烟的方法
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105011374A (zh) * 2015-06-05 2015-11-04 深圳市施美乐科技股份有限公司 复合功能型无烟香烟
CN107666836A (zh) * 2015-06-12 2018-02-06 菲利普莫里斯生产公司 电子吸烟制品中的生物学控制
US10687556B2 (en) 2015-06-12 2020-06-23 Philip Morris Products S.A. Biological control in electronic smoking articles
CN107666836B (zh) * 2015-06-12 2021-06-08 菲利普莫里斯生产公司 电子吸烟制品中的生物学控制
CN110475561A (zh) * 2017-03-23 2019-11-19 美纳里尼制药工业联合股份有限公司 具有抗氧化活性的保健性、饮食性和营养性组合物
CN111315373A (zh) * 2017-10-13 2020-06-19 瑟纳法姆工业合成有限公司 用于预防和/或治疗以神经元可塑性下降为特征、特别是突触可塑性下降为特征的中枢神经系统疾病的化合物和组合物

Also Published As

Publication number Publication date
WO2011041451A3 (en) 2011-10-06
JP2013506678A (ja) 2013-02-28
CA2776160A1 (en) 2011-04-07
US20110014277A1 (en) 2011-01-20
US8889194B2 (en) 2014-11-18
WO2011041451A2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
US8889194B2 (en) Smoking cessation with body weight maintenance and nutritional supplement
JP2013506678A5 (https=)
US6845777B2 (en) Composition to reduce or quit smoking addiction
ES2362220T3 (es) Control de glucosa en sangre en el tratamiento de diabetes usando insulina administrada por vía pulmonar en combinación con insulina basal.
US7560123B2 (en) Compositions and methods for nutrition supplementation
US7994226B2 (en) Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
US20100021570A1 (en) Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US20100098779A1 (en) Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US20080102138A1 (en) Replacement of Vitamins, Minerals and Neurotransmitter Losses from Tobacco Smoking
US20070190114A1 (en) Antioxidant health lozenges
CN101873855A (zh) 用于加入到烟草制品中的制剂和组成部分
US20120012123A1 (en) Compositions, articles and methods for preventing or reducing tobacco-associated damage
US20240285704A1 (en) Compositions comprising organic mineral chelates, niacinamide, and hemp oil and uses thereof for neuroprotection, cardioprotection, detoxification, immune support, and anti-aging
US8377907B1 (en) Compositions for treating alcohol hangover
TWI660726B (zh) 預防頭痛的組成物
US8968799B2 (en) Time delayed release mechanism for energizing composition and method of use
US20160095816A2 (en) Article and methods for oral self-administration of nicotine
BRPI0711996A2 (pt) preparaÇço farmacÊutica no formato de um folha, uso da preparaÇço farmacÊutica, uso de uma combinaÇço de agentes ativos, metodo para o tratamento terapÊutico de um individuo e mÉtodo para a produÇço de um forma de dosagem
US20230051702A1 (en) Compositions for prevention and treatment of symptoms associated with alcohol consumption
US20190365802A1 (en) Oral Delivery Product
US20080103111A1 (en) Smoking Cessation Treatment with Appetite Suppression
CN110573158A (zh) 可供人作为享乐或医疗产品消费的无烟草且无烟的产品以及治疗吸烟成瘾的方法
Choi et al. Vitamins B6 and cancer
US20130287704A1 (en) Article and methods for oral self-administration of nicotine
Nohr et al. Vitamins in milk and dairy products: B-group vitamins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711